Dimensional Fund Advisors
PLX icon

Dimensional Fund Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Dimensional Fund Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
493,424
+196,581
+66% +$416K ﹤0.01% 2837
2026
Q1 		$644K Buy
296,843
+268,099
+933% +$665K ﹤0.01% 2912
2025
Q4 		$51.5K Buy
28,744
+11,716
+69% +$24K ﹤0.01% 3208
2025
Q3 		$37.5K Sell
17,028
-28,543
-63% -$46.5K ﹤0.01% 3249
2025
Q2 		$67.7K Buy
+45,571
New +$93.2K ﹤0.01% 3215

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors's PLX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Protalix BioTherapeutics (PLX) stake by 66% in Q2 2026, buying an estimated $416K and bringing the position to 493,424 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

Dimensional Fund Advisors first reported a position in PLX in Q2 2025 and has held it in 5 quarters since. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Dimensional Fund Advisors held 493,424 shares of Protalix BioTherapeutics worth $1.15M as of Q2 2026.
  • Dimensional Fund Advisors bought 196,581 Protalix BioTherapeutics shares in Q2 2026, an estimated $416K.
  • Protalix BioTherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2837 holding.
  • Dimensional Fund Advisors first reported a position in Protalix BioTherapeutics in Q2 2025 and has held it in 5 quarters since.
  • 101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.